baricitinib vs ZL-82
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)
Result source: NCT03334422
ZL-82
Developed by Chengdu Zenitar Biomedical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07193589 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | ZL-82 |
|---|---|---|
| EASI-75 | 31.5% vs 17.2%+14.3 vs placeboNCT0342810065 other results
| —Not reported |
| IGA 0/1 with 2-point improvement | 13% vs 12.9%+0.1 vs placeboNCT034281005 other results
| —Not reported |
| EASI-90 | 16% vs 4.8%+11.2 vs placeboNCT0333439615 other results
| —Not reported |
| EASI, % change | -59.4% vs -34.8%−24.5 vs placeboNCT0333439612 other results
| —Not reported |
EASI-75
- baricitinib
- 31.5% vs 17.2%+14.3 vs placeboNCT03428100
65 other results
- 27.6% vs 17.2% NCT03428100
- 29.5% vs 8.2% NCT03435081
- 39.8% vs 54.3% NCT03334435
- 73.8% vs 43.5% NCT03334435
- 37% vs 26.9% NCT03428100
- 25% vs 17.2% NCT03428100
- 47.7% vs 22.9% NCT03733301
- 40.9% vs 54.3% NCT03334435
- 30.3% vs 26.9% NCT03428100
- 27.6% vs 17.2% NCT03428100
- 12.9% vs 8.2% NCT03435081
- 76.7% vs 55.1% NCT03334435
- 79.8% vs 44.6% NCT03334435
- 93% vs 63.3% NCT03334435
- 51.4% vs 38.5% NCT03334435
- 42.9% vs 38.2% NCT03334435
- 51.4% vs 44.2% NCT03334435
- 44.4% vs 47.1% NCT03334435
- 24.8% vs 8.8% NCT03334396
- 21.1% vs 6.1% NCT03334422
- 61.5% vs 71.4% NCT03334435
- 64.3% vs 42.3% NCT03334435
- 55.6% vs 55.9% NCT03334435
- 58.3% vs 43.5% NCT03334435
- 72.8% vs 43.5% NCT03334435
- 74.4% vs 55.1% NCT03334435
- 83.3% vs 55.1% NCT03334435
- 58.3% vs 44.6% NCT03334435
- 73.9% vs 44.6% NCT03334435
- 68.2% vs 72.4% NCT03428100
- 76.7% vs 63.3% NCT03334435
- 83.3% vs 63.3% NCT03334435
- 53.2% vs 71.4% NCT03334435
- 55.1% vs 71.4% NCT03334435
- 64.8% vs 38.5% NCT03334435
- 52.8% vs 38.2% NCT03334435
- 74.1% vs 44.2% NCT03334435
- 47.2% vs 47.1% NCT03334435
- 18.7% vs 8.8% NCT03334396
- 17.9% vs 6.1% NCT03334422
- 70.4% vs 42.3% NCT03334435
- 67.9% vs 55.9% NCT03334435
- 43.1% vs 22.9% NCT03733301
- 58.2% vs 43.5% NCT03334435
- 63.6% vs 62.1% NCT03428100
- 79.2% vs 55.1% NCT03334435
- 65.6% vs 54.3% NCT03334435
- 70.6% vs 72.4% NCT03428100
- 69.2% vs 44.6% NCT03334435
- 89.6% vs 63.3% NCT03334435
- 44.4% vs 71.4% NCT03334435
- 76.5% vs 62.1% NCT03428100
- 51.1% vs 38.5% NCT03334435
- 33.3% vs 26.9% NCT03428100
- 46.7% vs 44.2% NCT03334435
- 30.1% vs 17.2% NCT03428100
- 17.3% vs 8.8% NCT03334396
- 12.8% vs 6.1% NCT03334422
- 62.2% vs 42.3% NCT03334435
- 22.6% vs 17.2% NCT03428100
- 32.2% vs 32% NCT03952559
- 40% vs 32% NCT03952559
- 52.5% vs 32% NCT03952559
- 85.7% vs 72.4% NCT03428100
- 57.1% vs 62.1% NCT03428100
- ZL-82
- —Not reported
IGA 0/1 with 2-point improvement
- baricitinib
- 13% vs 12.9%+0.1 vs placeboNCT03428100
5 other results
- 21.7% vs 9.7% NCT03428100
- 18.9% vs 12.9% NCT03428100
- 15.1% vs 9.7% NCT03428100
- 20.4% vs 12.9% NCT03428100
- 12.9% vs 9.7% NCT03428100
- ZL-82
- —Not reported
EASI-90
- baricitinib
- 16% vs 4.8%+11.2 vs placeboNCT03334396
15 other results
- 13% vs 2.5% NCT03334422
- 14.1% vs 6.5% NCT03428100
- 24.3% vs 13.8% NCT03733301
- 10.6% vs 4.8% NCT03334396
- 8.9% vs 2.5% NCT03334422
- 10.3% vs 6.5% NCT03428100
- 20.5% vs 3.4% NCT03435081
- 16.5% vs 13.8% NCT03733301
- 8.7% vs 4.8% NCT03334396
- 6.4% vs 2.5% NCT03334422
- 8.6% vs 6.5% NCT03428100
- 7.5% vs 3.4% NCT03435081
- 11.6% vs 12.3% NCT03952559
- 21.7% vs 12.3% NCT03952559
- 30% vs 12.3% NCT03952559
- ZL-82
- —Not reported
EASI, % change
- baricitinib
- -59.4% vs -34.8%−24.5 vs placeboNCT03334396
12 other results
- -54.9% vs -28.9% NCT03334422
- -63.3% vs -42.7% NCT03428100
- -67.2% vs -45.1% NCT03733301
- -51.9% vs -34.8% NCT03334396
- -56.0% vs -42.7% NCT03428100
- -54.8% vs -28.9% NCT03334422
- -54.4% vs -34.1% NCT03435081
- -58.2% vs -45.1% NCT03733301
- -48.2% vs -34.8% NCT03334396
- -41.7% vs -28.9% NCT03334422
- -60.3% vs -42.7% NCT03428100
- -46.7% vs -34.1% NCT03435081
- ZL-82
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ZL-82: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. baricitinib: 4 of 4 rows · ZL-82: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib |
|---|---|
| Dropout rate | 4%4 mga NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.7%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4.9%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 98%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 97.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 7.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 6.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 14%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 13%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 8.3%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 32.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%4 mga NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.6%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 2.7%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 0.9%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 8.1%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.6%4 mga NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results0%4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 7.3%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 1.7%Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0.8%Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 9.5%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 13.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 5.4%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 6.4%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.3%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 4.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 9.4%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 2.2%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 28.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.9%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 11.1%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 19.2%2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 9.1%Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 12.5%2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 7.5%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 2.9%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 15.4%1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 21.4%1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0.7%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 1.8%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence 2.6%4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 5.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 4 mga nasopharyngitis 9.6% (placebo 10.4%) headache 8% (placebo 6.4%) cough 3.2% (placebo 0.8%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 47 more results4 mg abdominal pain 12.5% (placebo 0.4%) nausea 12.5% (placebo 0.8%) oedema peripheral 12.5% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg headache 11.4% (placebo 6.4%) nasopharyngitis 9.8% (placebo 10.4%) abdominal pain 2.4% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg pyrexia 12.5% (placebo 0%) urinary tract infection 12.5% (placebo 1.6%) abdominal pain 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 17.3% (placebo 10.4%) diarrhoea 7.1% (placebo 2.8%) headache 5.5% (placebo 6.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg pyrexia 20% (placebo 0%) abdominal pain 0% (placebo 0.4%) anaemia 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4 mg headache 8.9% (placebo 2%) nasopharyngitis 8.1% (placebo 12.3%) blood creatine phosphokinase increased 5.7% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg nasopharyngitis 13% (placebo 12.3%) headache 7.3% (placebo 2%) herpes simplex 5.7% (placebo 0.8%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 10.5% (placebo 12.3%) headache 4.8% (placebo 2%) blood creatine phosphokinase increased 3.2% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 High Dose abdominal pain 5% (placebo 2.5%) acne 5% (placebo 4.1%) headache 5% (placebo 8.2%) NCT03952559 · Phase 3 · registry result, not featured evidence Low Dose headache 5.8% (placebo 8.2%) bronchitis 5% (placebo 0.8%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence Mid Dose headache 9.2% (placebo 8.2%) abdominal pain 4.2% (placebo 2.5%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence High Dose nasopharyngitis 6.1% (placebo 4.9%) abdominal pain upper 3% (placebo 0.8%) chapped lips 3% (placebo 0%) NCT03952559 · Phase 3 · registry result, not featured evidence 4 mg covid-19 11% (placebo 2.2%) herpes zoster 9.8% (placebo 0%) nasopharyngitis 9.8% (placebo 5.4%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 2.2%) nasopharyngitis 13.1% (placebo 5.4%) blood creatine phosphokinase increased 6% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 16.4% (placebo 5.4%) upper respiratory tract infection 5.9% (placebo 4.3%) oral herpes 5.4% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 13.3% (placebo 2.2%) nasopharyngitis 10.8% (placebo 5.4%) headache 5.6% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 15.2% (placebo 2.2%) nasopharyngitis 10.9% (placebo 5.4%) headache 5.4% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.5% (placebo 5.4%) urinary tract infection 7.1% (placebo 1.1%) covid-19 4.8% (placebo 2.2%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 13.8% (placebo 5.4%) headache 6% (placebo 3.3%) upper respiratory tract infection 5.6% (placebo 4.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 21.9% (placebo 2.2%) alanine aminotransferase increased 9.4% (placebo 0%) dermal cyst 6.3% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 9.9% (placebo 2.2%) vulvovaginal candidiasis 6.7% (placebo 0%) folliculitis 5.5% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 20% (placebo 5.4%) pyrexia 4.4% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 37% (placebo 10.3%) influenza 15.2% (placebo 3.4%) headache 10.9% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 13.8%) dysmenorrhoea 14.3% (placebo 0%) upper respiratory tract infection 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 57.1% (placebo 10.3%) covid-19 28.6% (placebo 13.8%) gastroenteritis 28.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 4 mg nasopharyngitis 50% (placebo 10.3%) abdominal pain upper 16.7% (placebo 0%) migraine 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 2 mg nasopharyngitis 18.8% (placebo 10.3%) upper respiratory tract infection 18.8% (placebo 3.4%) arthralgia 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 4 mg covid-19 25% (placebo 13.8%) bronchitis 18.8% (placebo 0%) herpes simplex 18.8% (placebo 6.9%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 19.6% (placebo 10.3%) influenza 8.2% (placebo 3.4%) headache 7.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 22.7% (placebo 10.3%) covid-19 18.2% (placebo 13.8%) herpes zoster 13.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg covid-19 14.8% (placebo 13.8%) vulvovaginal candidiasis 14.3% (placebo 0%) nasopharyngitis 11.1% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 4 mg covid-19 19.2% (placebo 13.8%) herpes zoster 15.4% (placebo 0%) skin infection 15.4% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 2 mg acne 9.1% (placebo 0%) anaemia 9.1% (placebo 0%) covid-19 9.1% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg headache 20% (placebo 3.4%) vulvovaginal candidiasis 20% (placebo 0%) covid-19 16% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 1 mg nasopharyngitis 33.3% (placebo 10.3%) covid-19 12.5% (placebo 13.8%) pain in extremity 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 17.2% (placebo 10.3%) folliculitis 9.7% (placebo 0%) headache 8.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg dysmenorrhoea 23.1% (placebo 0%) covid-19 17.6% (placebo 13.8%) nasopharyngitis 11.8% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 2 mg herpes simplex 15.4% (placebo 6.9%) herpes zoster 15.4% (placebo 0%) nasopharyngitis 15.4% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 4 mg conjunctivitis 21.4% (placebo 0%) covid-19 21.4% (placebo 13.8%) uterine polypectomy 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 6.9% (placebo 6.2%) nasopharyngitis 6.2% (placebo 7.5%) diarrhoea 4.1% (placebo 1.4%) NCT03435081 · Phase 3 · registry result, not featured evidence 2 mg prostate cancer 9.1% (placebo 0%) upper respiratory tract infection 8.6% (placebo 6.2%) urinary tract infection 8.6% (placebo 2.1%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 6.1% (placebo 6.2%) back pain 2% (placebo 0.7%) blood creatine phosphokinase increased 2% (placebo 0.7%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 10.5% (placebo 6.2%) ovarian cyst ruptured 6.7% (placebo 0%) actinic keratosis 5.3% (placebo 0%) NCT03435081 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 15.3% (placebo 12%) folliculitis 5.4% (placebo 0%) upper respiratory tract infection 2.7% (placebo 1.9%) NCT03733301 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 11% (placebo 12%) upper respiratory tract infection 7.3% (placebo 1.9%) folliculitis 3.7% (placebo 0%) NCT03733301 · Phase 3 · registry result, not featured evidence 4 mg blood creatine phosphokinase increased 13.2% (placebo 2%) headache 13.2% (placebo 0%) nasopharyngitis 10.5% (placebo 4.1%) NCT02576938 · Phase 2 · registry result, not featured evidence 2 mg dermatitis atopic 8.1% (placebo 10.2%) gastrooesophageal reflux disease 5.4% (placebo 0%) headache 5.4% (placebo 0%) NCT02576938 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 42 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
show 5 more results
show 65 more results
show 15 more results
show 12 more results
show 15 more results
show 17 more results
show 15 more results
show 15 more results
show 17 more results
show 15 more results
show 17 more results
show 15 more results
+ 40 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · ZL-82's landscape